The Medicine Maker | The Medicine Maker

Musings from The Power List: Miguel Forte

September 8, 2026

Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy

4 min read

Cell & Gene

CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up

Cell & Gene

Manufacturing Reality Behind Personalized Cancer Vaccines

As personalized cancer vaccines move closer to commercialization, manufacturers must rethink DNA production to deliver batch-for-one treatments with the required speed, consistency, and quality

Research News

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

Small Molecules

Musings from The Power List: Peng Lu

Peng Lu argues that small molecules remain indispensable as AI transforms drug development

Cell & Gene Small Molecules Biopharma Future of Pharma

The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.

Our celebration of the most inspirational and influential leaders in medicine.

Find out more

Ann Cleves

VP of Application Science, BioPharmics Division, Optibrium

View Profile

Bruce Levine

Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine

View Profile

Musings from The Power List: Claudia Zylberberg

Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale

Read the article

All the latest Medicine Maker articles.

Future of Pharma Future of Pharma Business & Trends Power List

What Will Drug Development Look Like in 2036?

September 3, 2026

Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry

7 min read

Drug Discovery

How Glycosylation Is Shaping Cancer Biomarker Discovery

September 2, 2026

Glycosylation could offer cancer researchers a new way to understand tumors, identify biomarkers, and develop more precise therapies

3 min read

Biopharma Biopharma Regulation & Standards Outsourcing

China’s Biopharma Homecoming

September 1, 2026

Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han

7 min read

Cell & Gene Industry News Research News Business & Trends

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

August 31, 2026

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

4 min read

Biopharma Biopharma

Breaking Manufacturing Bottlenecks in Nucleic Acid Therapeutics

August 31, 2026

New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products

4 min read

Development & Clinical Small Molecules Interviews Power List

Musings from The Power List: Christine Allen

August 28, 2026

Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise

2 min read

Biopharma Technology & Manufacturing

The Hidden Complexity of Stability Storage

August 27, 2026

Why preserving samples is a scientific, regulatory, and operational challenge – and what’s at risk when it goes wrong

9 min read

Biopharma Interviews Business & Trends

Green Shoots, Gray Skies

August 26, 2026

Jon Rees sees signs of recovery following biotech's post-pandemic funding reset, but there’s no going back to the “old normal”

9 min read

Biopharma Industry News Development & Clinical Drug Discovery

Phase III Success Marks Milestone for Personalized Cancer Vaccines

August 26, 2026

Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field

7 min read

Drug Discovery Business & Trends

Data Quality: Drug Discovery AI’s Indispensable Foundation

August 25, 2026

Reliable discovery insights depend on models grounded in curated, verifiable scientific knowledge

5 min read

Top Stories